middle.news
Cynata’s Cymerus platform survives as failed trials trigger a strategic reset
5:24pm on Monday 28th of September, 2026 AEST
•
Biotechnology
Read Story
Cynata’s Cymerus platform survives as failed trials trigger a strategic reset
5:24pm on Monday 28th of September, 2026 AEST
Key Points
Phase 2 CYP-001 and Phase 3 CYP-004 trials failed to demonstrate efficacy
$9.25 million annual loss and $553,774 net liability position
$1.35 million impairment recognised against licensed intellectual property
All employee positions made redundant after year end
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Cynata Therapeutics (ASX:CYP)
OPEN ARTICLE